NEWS
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease
Acumen Pharmaceuticals presented data on using pTau217 assay as an efficient screening tool for their Phase 2 ALTITUDE-AD clinical trial of sabirnetug for early Alzheimer's disease. The assay, with a threshold of ≥0.15 pg/mL, effectively identifies potential participants likely to have amyloid in the brain, reducing unnecessary amyloid PET scans and lumbar procedures. 74% of participants with elevated pTau217 met amyloid burden eligibility requirements, compared to 40% in their Phase 1 trial without this screening approach. The study is enrolling at 75 sites across multiple regions, with completion expected in first half of 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2693Followers
108Following
29KVisitors
Follow